Improving the outcome in treatment-resistant schizophrenia

Friday, 18 March, 2016
The faster schizophrenia patients receive effective treatment, the better their prognosis. EU-funded researchers are establishing a profile of individuals unlikely to respond to the drugs used in first-line treatment, for whom the last-resort antipsychotic clozapine should be considered sooner. They are also improving the safety of this drug.

The Crestar project looked for genetic and clinical biomarkers that indicate whether a person suffering from schizophrenia is likely to respond to standard antipsychotic drugs or whether clozapine is likely to be required. Coordinated by King’s College London, it draws on thousands of DNA samples donated by patients and healthy individuals across Europe.

Read more

Project: 
Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia
Project Acronym: 
CRESTAR
Article
#H2020